Myotonic Dystrophy-1 Complicated by Factor-V (Leiden) Mutation

被引:1
|
作者
Finsterer, Josef [1 ]
Stoellberger, Claudia [2 ]
机构
[1] Krankenanstalt Rudolfstiftung Wien, A-1030 Vienna, Austria
[2] Krankenanstalt Rudolfstiftung Wien, Med Dept Cardiol & Intens Care Med 2, A-1030 Vienna, Austria
关键词
D O I
10.1155/2015/271639
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Presence of a factor-V Leidenmutation in a patient withmyotonic dystrophy type 1 (DM1) has been reported only once. Here we report the second DM1 patient carrying a factor-V mutation who died from long-term complications of this mutation. Case Report. A 66-year-oldDM1 patient withmulti-organ-disorder syndrome developed a first deep venous thrombosis (DVT) and consecutive pulmonary embolism (PE) at age 50 y. Acetyl-salicylic acidwas given. One year later he experienced a secondDVT; that is why phenprocoumon was started. Despite anticoagulation, he experienced a third DVT bilaterally and a second PE bilaterally at 61 y; that is why a vena cava filter was additionally deployed. Despite therapeutic anticoagulation, he experienced a vena cava filter thrombosis at age 62 y. Genetic workup revealed a heterozygous factor-V mutation in addition to a CTG-repeat expansion of 500. As a consequence of PE he developed chronic obstructive pulmonary disease and experienced recurrent pulmonary infections, which were lastly responsible for decease at age 66 y despite intensive care measures. Conclusion. The heterozygous Leidenmutation may severely affect DM1 patients to such a degree that they die from its complications. If DM1 patients present with unusual manifestations, search for causes other than a CTG-repeat expansion is indicated.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation
    Ymir Saemundsson
    Signý Vala Sveinsdottir
    Henrik Svantesson
    Peter J. Svensson
    Journal of Thrombosis and Thrombolysis, 2013, 36 : 324 - 331
  • [22] The distribution of Factor V Leiden mutation
    Eroglu, Aydan
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (03) : 341 - 342
  • [23] Tamoxifen and the Factor V Leiden Mutation
    Cuzick, Jack
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (13) : 918 - U1
  • [24] Factor V Leiden mutation and pregnancy
    Langan, RC
    JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE, 2004, 17 (04): : 306 - 308
  • [25] Factor V Leiden mutation in pregnancy
    Cohen, SM
    JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING, 2004, 33 (03): : 348 - 353
  • [26] FACTOR-V LEIDEN AND RISKS OF RECURRENT IDIOPATHIC VENOUS THROMBOEMBOLISM
    RIDKER, PM
    MILETICH, JP
    STAMPFER, MJ
    GOLDHABER, SZ
    LINDPAINTNER, K
    HENNEKENS, CH
    CIRCULATION, 1995, 92 (10) : 2800 - 2802
  • [27] The distribution of Factor V Leiden mutation
    Aydan Eroğlu
    Journal of Thrombosis and Thrombolysis, 2013, 36 : 341 - 342
  • [28] Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation
    Saemundsson, Ymir
    Sveinsdottir, Signy Vala
    Svantesson, Henrik
    Svensson, Peter J.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (03) : 324 - 331
  • [29] Homozygous factor V Leiden and compound heterozygosity for factor V Leiden and prothrombin mutation
    Saemundsson, Y.
    Sveinsdottir, S., V
    Svantesson, H.
    Svensson, P. J.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 151 - 151
  • [30] LOW-PREVALENCE OF THE FACTOR-V LEIDEN MUTATION AMONG SEVERE HEMOPHILIACS WITH A MILDER BLEEDING DIATHESIS
    ARBINI, AA
    MANNUCCI, PM
    BAUER, KA
    THROMBOSIS AND HAEMOSTASIS, 1995, 74 (05) : 1255 - 1258